Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Timothy Beukelman; Aimee Lougee; Roland A Matsouaka; David Collier; Dax G Rumsey; Jennifer Schenfeld; Scott Stryker; Marinka Twilt; Yukiko Kimura; CARRA Registry Investigators

doi:10.1186/s12969-021-00625-y

Back

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Journal article

Open access

Peer reviewed

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Timothy Beukelman, Aimee Lougee, Roland A Matsouaka, David Collier, Dax G Rumsey, Jennifer Schenfeld, Scott Stryker, Marinka Twilt, Yukiko Kimura and CARRA Registry Investigators

Pediatric rheumatology online journal, Vol.19(1), pp.131-131

08/21/2021

DOI: 10.1186/s12969-021-00625-y

PMCID: PMC8380401

PMID: 34419107

Files and links (1)

url

https://doi.org/10.1186/s12969-021-00625-yView

Published (Version of record) Open Access

Abstract

We aimed to characterize etanercept (ETN) use in juvenile idiopathic arthritis (JIA) patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. The CARRA Registry is a convenience cohort of patients with paediatric onset rheumatic diseases, including JIA. JIA patients treated with ETN for whom the month and year of ETN initiation were available were included. Patterns of ETN and methotrexate (MTX) use were categorized as follows: combination therapy (ETN and MTX started concurrently), step-up therapy (MTX started first and ETN added later), switchers (MTX started and then stopped when or before ETN started), MTX add-on (ETN started first and MTX added later), and ETN only (no MTX use). Data were described using parametric and non-parametric statistics as appropriate. Two thousand thirty-two of the five thousand six hundred forty-one patients with JIA met inclusion criteria (74% female, median age at diagnosis 6.0 years [interquartile range 2.0, 11.0]. Most patients (66.9%) were treated with a non-biologic disease modifying anti-rheumatic drug (DMARD), primarily MTX, prior to ETN. There was significant variability in patterns of MTX use prior to starting ETN. Step-up therapy was the most common approach. Only 34.0% of persistent oligoarticular JIA patients continued treatment with a non-biologic DMARD 3 months or more after ETN initiation. ETN persistence overall was 66.3, 49.4, and 37.3% at 24, 36 and 48 months respectively. ETN persistence among spondyloarthritis patients (enthesitis related arthritis and psoriatic JIA) varied by MTX initiation pattern, with higher ETN persistence rates in those who initiated combination therapy (68.9%) and switchers/ETN only (73.3%) patients compared to step-up (65.4%) and MTX add-on (51.1%) therapy. This study characterizes contemporary patterns of ETN use in the CARRA Registry. Treatment was largely in keeping with American College of Rheumatology guidelines.

Arthritis, Juvenile - diagnosis

Arthritis, Juvenile - drug therapy

Arthritis, Juvenile - epidemiology

Arthritis, Juvenile - immunology

Child

Clinical Protocols

Drug Monitoring - methods

Drug Therapy, Combination - methods

Duration of Therapy

Etanercept - administration & dosage

Etanercept - adverse effects

Female

Humans

Immunosuppressive Agents - administration & dosage

Immunosuppressive Agents - adverse effects

Male

Medication Therapy Management - statistics & numerical data

Methotrexate - administration & dosage

Methotrexate - adverse effects

Registries - statistics & numerical data

Tumor Necrosis Factor Inhibitors - administration & dosage

Tumor Necrosis Factor Inhibitors - adverse effects

United States - epidemiology

Details

Title: Subtitle: Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Creators: Timothy Beukelman - University of Alabama at Birmingham
Aimee Lougee - Duke University
Roland A Matsouaka - Duke University
David Collier - Amgen (United States)
Dax G Rumsey - University of Alberta
Jennifer Schenfeld - Amgen (United States)
Scott Stryker - Amgen (United States)
Marinka Twilt - Alberta Children's Hospital
Yukiko Kimura - Hackensack University Medical Center
CARRA Registry Investigators
Contributors: S Lieberman (Contributor) - University of Iowa, Rheumatology, Allergy, and Immunology
Resource Type: Journal article
Publication Details: Pediatric rheumatology online journal, Vol.19(1), pp.131-131
DOI: 10.1186/s12969-021-00625-y
PMID: 34419107
PMCID: PMC8380401
NLM abbreviation: Pediatr Rheumatol Online J
ISSN: 1546-0096
eISSN: 1546-0096
Grant note: (none) / Amgen
Language: English
Date published: 08/21/2021
Academic Unit: Stead Family Department of Pediatrics; Rheumatology, Allergy, and Immunology
Record Identifier: 9984353843602771

Metrics

7 Record Views

4 Times Cited - Web of Science